How many insider trades does FilingIQ track for IGC?

FilingIQ tracks 265 Form 4 insider transactions for IGC (IGC Pharma, Inc.), covering filings from Apr 4, 2014 onwards. 20 of those were filed in the last 90 days.

Are IGC insiders net buyers or net sellers?

Across the full Form 4 history for IGC, 1 transactions (0%) were open-market purchases and 30 (11%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IGC insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IGC in?

IGC Pharma, Inc. (IGC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.07M.

IGC insider trading

NYSE American Healthcare

IGC Pharma, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

265

Last 90 days

Buys / sells

0% / 11%

Market cap

$26.07M

About IGC Pharma, Inc.

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Company website: igcpharma.com

IGC insider activity at a glance

FilingIQ has scored 265 insider transactions for IGC since Apr 4, 2014. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 1 open-market purchases and 30 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IGC insider trades is 61.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IGC trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for IGC?: FilingIQ tracks 265 Form 4 insider transactions for IGC (IGC Pharma, Inc.), covering filings from Apr 4, 2014 onwards. 20 of those were filed in the last 90 days.
Are IGC insiders net buyers or net sellers?: Across the full Form 4 history for IGC, 1 transactions (0%) were open-market purchases and 30 (11%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IGC insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IGC in?: IGC Pharma, Inc. (IGC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.07M.

Methodology & sources

Every IGC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.